RxDoctor Payments Data

Diane Mladjen, APRN

Family · Sandy Hook, CTNPI 1457991333

Payments from drug & device makers

$3,636in general payments, 2019–2025

Across 119 payments — averaging $30.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Johnson & Johnson$492
  • Pfizer$273
  • Sumitomo Pharma America, Inc.$194
  • Acerus Pharmaceuticals Corporation$160
  • Urovant Sciences Inc$155
  • plus $1K from 24 others

What the payments were for

  • Travel & lodging$44412%
  • Food & beverage$3,19288%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,636 in reported general payments places this provider in the 85th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$77,608
Medicare patients
380
Services billed
3,568

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron295$225,097
MyrbetriqMirabegron115$71,283
XyostedTestosterone Enanthate35$29,445
Mirabegron ErMirabegron18$8,806
Tamsulosin Hcl448$6,073
Testosterone26$4,361
Methenamine Hippurate61$4,034
Testosterone Cypionate66$3,980
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav84$3,354
Cefpodoxime Proxetil32$2,479
Estradiol23$1,763
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst112$1,462
Oxybutynin Chloride ErOxybutynin Chloride103$1,444
Finasteride126$1,230
Ciprofloxacin Hcl124$1,182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$194$225,097295 claims
Astellas Pharma US IncMyrbetriq$100$71,283115 claims
Antares Pharma, Inc.Xyosted$126$29,44535 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,596 family providers in Connecticut.

Other family in Sandy Hook

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →